AGTC Genomics

23/05/2026

𝗜𝘀 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗕𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗘𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗻 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲?

From pharmacogenomics and hereditary disease screening to cancer genomics and personalized treatment selection, genomics is rapidly reshaping the future of internal medicine.

But many clinicians still ask:
• When should genomic testing be considered?
• Which test is most appropriate?
• How do we interpret complex genomic reports?
• How can genomic insights truly improve patient care?

In this educational article, we explore how physicians can:
✔ Recognize when genomics matters
✔ Choose the right tests
✔ Interpret complex data with confidence
✔ Translate genomic insights into better patient outcomes

Precision medicine is no longer the future — it is becoming part of everyday clinical practice.

https://www.agtcgenomics.com/post/genomics-in-internal-medicine-from-data-to-better-patient-care

Genomics in Internal Medicine: From Data to Better Patient Care

22/05/2026

𝗙𝗿𝗼𝗺 𝗕𝗶𝗼𝗽𝘀𝘆 𝘁𝗼 𝗕𝗲𝘁𝘁𝗲𝗿 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 — 𝗧𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆

Cancer care is rapidly evolving — and comprehensive genomic profiling is becoming an essential tool in precision oncology.

AGTC Genomics’ OncoDx™ Comprehensive Genomic Profiling (CGP) provides a streamlined journey from biopsy to actionable clinical insights through one comprehensive test and one consolidated report.

By analyzing up to 523 genes together with important genomic signatures such as TMB, MSI, and HRR, OncoDx™ helps clinicians uncover actionable alterations linked to targeted therapies, immunotherapies, and clinical trials.

The OncoDx™ workflow:
🔬 Sample collection
🧬 Advanced deep-sequencing analysis
💻 Bioinformatics interpretation
👨‍⚕️ Clinical review aligned with guidelines
📄 Actionable reporting for precision treatment decisions

Why it matters:
✔ Reduce the need for sequential testing
✔ Preserve precious biopsy samples
✔ Faster access to molecular insights
✔ Applicable for both solid and blood cancers
✔ Local testing in a CAP-accredited and ISO 15189-certified laboratory with results in 7–14 working days

At AGTC Genomics, we are committed to transforming genomic data into personalized cancer care — improving outcomes through precision medicine.

22/05/2026

𝗟𝗶𝗾𝘂𝗶𝗱𝗗𝘅𝗧𝗠 – 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗮 𝗦𝗶𝗺𝗽𝗹𝗲 𝗕𝗹𝗼𝗼𝗱 𝗗𝗿𝗮𝘄

What if cancer monitoring could become less invasive, faster, and more precise?

Introducing LiquidDx™ – Circulating Tumour DNA (ctDNA) Liquid Biopsy by AGTC Genomics.

LiquidDx™ leverages advanced next-generation sequencing (NGS) technology to analyze circulating tumour DNA (ctDNA) from a simple blood sample—providing real-time genomic insights that support precision oncology and personalized treatment decisions.

Key advantages of LiquidDx™:
✔ Non-invasive alternative to repeated tissue biopsies
✔ Detect actionable mutations in real time
✔ Monitor treatment response and disease progression
✔ Identify emerging resistance mutations
✔ Comprehensive genomic profiling from blood
✔ Performed in a CAP-Accredited laboratory

Liquid biopsy is transforming how clinicians manage metastatic cancer—offering smarter monitoring, improved accessibility, and faster decision-making for better patient outcomes.

At AGTC Genomics, we are committed to advancing precision medicine through cutting-edge genomics technologies across Asia.

📍 Available in Malaysia and through regional partners
📞 +6012 520 7981
📧 info@agtcgenomics.com
🌐 www.agtcgenomics.com

21/05/2026

𝗢𝗻𝗲 𝗕𝗹𝗼𝗼𝗱 𝗧𝗲𝘀𝘁. 𝗢𝘃𝗲𝗿 𝟭𝟭𝟬 𝗖𝗮𝗻𝗰𝗲𝗿𝘀. 𝗔 𝗟𝗶𝗳𝗲𝘁𝗶𝗺𝗲 𝗼𝗳 𝗣𝗼𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀.

What if one simple blood test could change the future of cancer care?

CancerScreenDx™ by AGTC Genomics is an advanced Multi-Cancer Early Detection (MCED) solution designed to detect over 110 types of cancer from a single blood draw—helping patients discover risks earlier, before symptoms become advanced.

With accurate cancer signal detection and tissue-of-origin prediction, CancerScreenDx supports faster diagnosis, earlier intervention, and more effective treatment planning.

From lung, breast, colorectal, liver, ovarian, pancreatic cancers and many more—this is precision medicine built for proactive healthcare.

✔ Simple – Just one blood draw
✔ Accurate – Detects cancer signals and predicts origin
✔ Comprehensive – Covers 110+ cancer types
✔ Fast & Reliable – Results within 7–14 working days from our CAP-accredited laboratory

Because early answers create a lifetime of possibilities.

Advanced genomics. Meaningful insights. Better outcomes.

21/05/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗮𝗻𝗱 𝗠𝗮𝗻𝘂𝗹𝗶𝗳𝗲 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲 𝘁𝗼 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮

We are proud to announce the collaboration between AGTC Genomics and Manulife Malaysia to expand access to Multi-Cancer Detection (MCD) and Pharmacogenomics (PGx) testing in Malaysia.

As cancer cases and healthcare costs continue to rise nationwide, early detection and personalized medicine are becoming increasingly important in improving patient outcomes while reducing the long-term burden of cancer care.

Through this collaboration, we hope to increase awareness and accessibility of advanced genomic technologies such as:

• 🔬 Multi-Cancer Detection (MCD) – screening for 110+ cancers from a single blood draw using advanced next-generation sequencing (NGS)

• 💊 Pharmacogenomics (PGx) – helping clinicians personalize medication selection and dosing based on an individual’s genetic profile

At AGTC Genomics, we believe the future of healthcare lies in prevention, early detection, and precision medicine. By combining innovation, genomics, and clinical insights, we aim to support Malaysians with more proactive and personalized healthcare solutions.

As a Malaysian CAP-accredited genomics laboratory, AGTC Genomics remains committed to strengthening local precision medicine capabilities and making advanced genomic testing more accessible across the country.

AGTC Genomics and Manulife Collaborate to Strengthen Early Cancer Detection and Precision Medicine in Malaysia

20/05/2026

🧬 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗔𝗰𝗿𝗼𝘀𝘀 𝗦𝗼𝘂𝘁𝗵𝗲𝗮𝘀𝘁 𝗔𝘀𝗶𝗮

AGTC Genomics is proud to provide comprehensive, CAP-accredited cancer genomics solutions designed to support the entire cancer care continuum — from hereditary risk assessment and early detection to precision treatment selection and recurrence monitoring.

Our integrated oncology portfolio includes:

🔹 CancerRiskDx™ – Hereditary Cancer Testing
Identify inherited cancer risks through comprehensive germline genomic analysis for proactive prevention and family health management.

🔹 CancerScreenDx™ – Multi-Cancer Early Detection (MCED)
Advanced blood-based screening technology capable of detecting multiple cancers at an earlier stage, when treatment outcomes are often significantly improved.

🔹 OncoDx™ – Comprehensive Gene Profiling (CGP)
Actionable genomic insights to guide targeted therapy, immunotherapy, and precision oncology decisions.

🔹 LiquidDx™ – ctDNA Liquid Biopsy
Non-invasive real-time molecular profiling for therapy selection, monitoring, and disease progression assessment.

🔹 CancerTRACE™ – Minimal Residual Disease (MRD) Monitoring
Highly sensitive detection of residual disease and recurrence monitoring to support personalized follow-up care.

✅ CAP-Accredited Laboratory
✅ Advanced NGS & Bioinformatics
✅ Precision Oncology Expertise
✅ Faster Regional Access to Genomic Testing
✅ Personalized & Evidence-Based Cancer Care

🌏 Now supporting clinicians, hospitals, researchers, and patients across:
🇲🇾 Malaysia
🇸🇬 Singapore
🇻🇳 Vietnam
🇹🇭 Thailand
🇵🇭 Philippines

At AGTC Genomics, we believe the future of oncology lies in earlier detection, smarter molecular insights, and accessible precision medicine for every patient.

20/05/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗶𝘁𝗵 𝗠𝗲𝗱𝗶𝗹𝗮𝗯𝗼 𝗩𝗶𝗲𝘁𝗻𝗮𝗺 𝘁𝗼 𝗘𝘅𝗽𝗮𝗻𝗱 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗔𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗩𝗶𝗲𝘁𝗻𝗮𝗺

AGTC Genomics is proud to announce a strategic partnership with Medilabo Vietnam to expand access to advanced genomics and precision medicine solutions in Vietnam.

Through this collaboration, Medilabo Vietnam will gain access to 500+ advanced genomic and molecular diagnostic tests from AGTC Genomics’ CAP-accredited laboratory, covering preventive medicine, pharmacogenomics (PGx), cancer genomics, rare diseases, clinical metagenomics, infectious diseases, and many more.

A key highlight of the partnership is the introduction of AGTC Genomics’ Multi-Cancer Early Detection (MCED) technology, CancerScreenDx™, capable of screening for 110+ cancer types from a single blood draw with superior accuracy. CancerScreenDx™ MCED is also a -registered product recognized by the Malaysia Miinistry of Science, Technology and Innovation, reflecting AGTC Genomics’ commitment to local innovation and advanced precision medicine technologies.

This partnership reflects a shared commitment to advancing early detection, personalized healthcare, and precision medicine across Vietnam and Southeast Asia.



https://www.agtcgenomics.com/post/agtc-genomics-partners-with-medilabo-vietnam-to-expand-access-to-advanced-precision-medicine-and-mul

Bioeconomy Corporation
MRANTI
Kementerian Sains, Teknologi dan Inovasi (MOSTI)
Chang Lih Kang

AGTC Genomics Partners with Medilabo Vietnam to Expand Precision Medicine Access in Vietnam

20/05/2026

🚀 𝗪𝗘 𝗔𝗥𝗘 𝗛𝗜𝗥𝗜𝗡𝗚!
𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀.

We are looking for a passionate and motivated Sales & Marketing Executive to join our growing team in genomics and molecular diagnostics.

This role offers the opportunity to work closely with hospitals, clinicians, researchers, universities, and healthcare partners while promoting advanced genomic testing solutions including:

🧬 Oncology Profiling
🩸 Liquid Biopsy
🧪 Pharmacogenomics
🧫 Hereditary Disease Testing
🔬 Research & Genomics Services

At AGTC Genomics, you will gain exposure to cutting-edge technologies in precision medicine, regional collaborations, scientific conferences, and a fast-growing healthcare innovation ecosystem.

✨ Fresh graduates and candidates with up to 1 year of experience are encouraged to apply.

📍 Location: Bukit Jalil, Kuala Lumpur
📧 Send your CV to: info@agtcgenomics.com

Join us in advancing accessible and affordable precision medicine for Asia and beyond.

20/05/2026

𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗗𝗮𝘁𝗮 𝗶𝗻𝘁𝗼 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲

Every cancer is unique — and every patient deserves a treatment strategy guided by precision genomics.

AGTC Genomics’ OncoDx™ Comprehensive Genomic Profiling (CGP) empowers clinicians with deeper molecular insights to identify actionable alterations, personalize therapies, and support better treatment decisions.

Using a single comprehensive assay, OncoDx™ analyzes up to 523 genes together with important genomic signatures such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Repair (HRR).

Key advantages of OncoDx™:
✔ Comprehensive detection of SNVs, indels, CNVs, fusions, and splice variants
✔ Support for targeted therapies, immunotherapies, and clinical trials
✔ Applicable for both solid tumors and blood cancers
✔ Fast local turnaround time of 7–14 working days
✔ Performed in a CAP-accredited and ISO 15189-certified laboratory

Precision oncology is more than technology — it is about delivering the right care to the right patient at the right time.

At AGTC Genomics, we are committed to advancing health through accessible and high-quality precision medicine solutions.

19/05/2026

𝗢𝗻𝗲 𝗧𝗲𝘀𝘁. 𝗢𝘃𝗲𝗿 𝟭𝟭𝟬 𝗖𝗮𝗻𝗰𝗲𝗿𝘀. 𝗔 𝗕𝗲𝘁𝘁𝗲𝗿 𝗧𝗼𝗺𝗼𝗿𝗿𝗼𝘄.

What if one simple blood test could help detect over 110 types of cancer—before symptoms even appear?

CancerScreenDx™ by AGTC Genomics is redefining cancer screening through advanced Multi-Cancer Early Detection (MCED), using cutting-edge genomics to identify cancer signals early, when treatment is most effective.

From lung and colorectal to breast, liver, ovarian, pancreatic, and many more—CancerScreenDx provides a comprehensive, non-invasive solution from just a single blood draw.

✔ Simple
✔ Accurate
✔ Comprehensive
✔ Fast & Reliable

Performed in our CAP-accredited laboratory, CancerScreenDx helps clinicians and patients make earlier, smarter, and more confident healthcare decisions.

Because the best fight against cancer begins before it starts.

Advanced genomics. Personalized care. Better outcomes.